Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Aug 22;23(16):9470.
doi: 10.3390/ijms23169470.

Vaccine for Diabetes-Where Do We Stand?

Dinesh Kumar Chellappan  1 , Richie R Bhandare  2   3 , Afzal B Shaik  4 , Krishna Prasad  5 , Nurfatihah Azlyna Ahmad Suhaimi  6 , Wei Sheng Yap  6 , Arpita Das  7 , Pradipta Banerjee  8 , Nandini Ghosh  8 , Tanner Guith  8 , Amitava Das  8 , Sarannya Balakrishnan  9 , Mayuren Candasamy  1 , Jayashree Mayuren  10 , Kishneth Palaniveloo  11 , Gaurav Gupta  12   13   14 , Sachin Kumar Singh  15   16 , Kamal Dua  16   17
Affiliations
Review

Vaccine for Diabetes-Where Do We Stand?

Dinesh Kumar Chellappan et al. Int J Mol Sci. .

Abstract

Diabetes is an endocrinological disorder with a rapidly increasing number of patients globally. Over the last few years, the alarming status of diabetes has become a pivotal factor pertaining to morbidity and mortality among the youth as well as middle-aged people. Current developments in our understanding related to autoimmune responses leading to diabetes have developed a cause for concern in the prospective usage of immunomodulatory agents to prevent diabetes. The mechanism of action of vaccines varies greatly, such as removing autoreactive T cells and inhibiting the interactions between immune cells. Currently, most developed diabetes vaccines have been tested in animal models, while only a few human trials have been completed with positive outcomes. In this review, we investigate the undergoing clinical trial studies for the development of a prototype diabetes vaccine.

Keywords: GLP; clinical trials; diabetes; insulin; vaccines.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Different modes of prevention of diabetes.
Figure 2
Figure 2
A classification of different vaccines for treating diabetes.
Figure 3
Figure 3
T1DM and vaccine adjuvant’s mechanisms of action.
See this image and copyright information in PMC

References

    1. Nair M. Diabetes mellitus, part 1: Physiology and complications. Br. J. Nurs. 2007;16:184–188. doi: 10.12968/bjon.2007.16.3.22974. - DOI - PubMed
    1. Rewers M., Gottlieb P. Immunotherapy for the Prevention and Treatment of Type 1 Diabetes: Human trials and a look into the future. Diabetes Care. 2009;32:1769–1782. doi: 10.2337/dc09-0374. - DOI - PMC - PubMed
    1. Alwan A. Raising the priority accorded to diabetes in global health and development: A promising response. Int. J. Diabetes Mellit. 2010;3:139–140. doi: 10.1016/j.ijdm.2010.10.001. - DOI
    1. Slim I.B.H.S. Cardiovascular risk in type 1 diabetes mellitus. Indian J. Endocrinol. Metab. 2013;17((Suppl. 1)):S7–S13. doi: 10.4103/2230-8210.119489. - DOI - PMC - PubMed
    1. Diabetes. [(accessed on 1 June 2022)]. Available online: http://www.who.int/health-topics/diabetes#tab=tab_1.